Medicure Inc. (MCUJF) Set to Announce Earnings on Tuesday

Medicure Inc. (OTCMKTS:MCUJF) will be posting its quarterly earnings results after the market closes on Tuesday, November 21st. Analysts expect Medicure to post earnings of $0.18 per share for the quarter.

Shares of Medicure Inc. (OTCMKTS:MCUJF) remained flat at $$6.45 during trading hours on Friday. The company’s stock had a trading volume of 1,000 shares, compared to its average volume of 2,266. The stock has a market capitalization of $103.20, a P/E ratio of 6.82 and a beta of 0.32. Medicure Inc. has a 1-year low of $4.56 and a 1-year high of $7.96. The company has a debt-to-equity ratio of 1.60, a current ratio of 0.65 and a quick ratio of 0.43.

Separately, Zacks Investment Research upgraded shares of Medicure from a “hold” rating to a “buy” rating and set a $7.25 price target for the company in a report on Tuesday, October 3rd.

TRADEMARK VIOLATION NOTICE: “Medicure Inc. (MCUJF) Set to Announce Earnings on Tuesday” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://sportsperspectives.com/2017/11/17/medicure-inc-mcujf-set-to-announce-earnings-on-tuesday.html.

About Medicure

Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).

Receive News & Ratings for Medicure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply